Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin

Michael J. McNeil; Marguerite T. Parisi; Nobuko Hijiya; Soheil Meshinchi; Todd Cooper; Katherine Tarlock

doi:10.1097/MPH.0000000000001201

Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin

Michael J. McNeil^*, Marguerite T. Parisi, Nobuko Hijiya, Soheil Meshinchi, Todd Cooper, Katherine Tarlock

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Extramedullary leukemia (EML) is common in pediatric acute leukemia and can present at diagnosis or relapse. CD33 is detected on the surface of myeloid blasts in many patients with acute myelogenous leukemia and is the target of the antibody drug conjugate gemtuzumab ozogamicin (GO). Here we present 2 patients with CD33⁺ EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically ¹⁸fluorine fluorodeoxyglucose positron emission tomography/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33⁺ leukemia and the utility of ¹⁸fluorine fluorodeoxyglucose positron emission tomography/computed tomography monitoring in EML.

Original language	English (US)
Pages (from-to)	E174-E176
Journal	Journal of pediatric hematology/oncology
Volume	41
Issue number	3
DOIs	https://doi.org/10.1097/MPH.0000000000001201
State	Published - Apr 1 2019

Keywords

18F-FDG PET/CT
Extramedullary leukemia
Gemtuzumab ozogamicin

ASJC Scopus subject areas

Hematology
Oncology
Pediatrics, Perinatology, and Child Health

Access to Document

10.1097/MPH.0000000000001201

Cite this

@article{1d164b222cb64d249bb495cb64e78f41,

title = "Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin",

abstract = "Extramedullary leukemia (EML) is common in pediatric acute leukemia and can present at diagnosis or relapse. CD33 is detected on the surface of myeloid blasts in many patients with acute myelogenous leukemia and is the target of the antibody drug conjugate gemtuzumab ozogamicin (GO). Here we present 2 patients with CD33+ EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33+ leukemia and the utility of 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography monitoring in EML.",

keywords = "18F-FDG PET/CT, Extramedullary leukemia, Gemtuzumab ozogamicin",

author = "McNeil, {Michael J.} and Parisi, {Marguerite T.} and Nobuko Hijiya and Soheil Meshinchi and Todd Cooper and Katherine Tarlock",

year = "2019",

month = apr,

day = "1",

doi = "10.1097/MPH.0000000000001201",

language = "English (US)",

volume = "41",

pages = "E174--E176",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin

AU - McNeil, Michael J.

AU - Parisi, Marguerite T.

AU - Hijiya, Nobuko

AU - Meshinchi, Soheil

AU - Cooper, Todd

AU - Tarlock, Katherine

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Extramedullary leukemia (EML) is common in pediatric acute leukemia and can present at diagnosis or relapse. CD33 is detected on the surface of myeloid blasts in many patients with acute myelogenous leukemia and is the target of the antibody drug conjugate gemtuzumab ozogamicin (GO). Here we present 2 patients with CD33+ EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33+ leukemia and the utility of 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography monitoring in EML.

AB - Extramedullary leukemia (EML) is common in pediatric acute leukemia and can present at diagnosis or relapse. CD33 is detected on the surface of myeloid blasts in many patients with acute myelogenous leukemia and is the target of the antibody drug conjugate gemtuzumab ozogamicin (GO). Here we present 2 patients with CD33+ EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33+ leukemia and the utility of 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography monitoring in EML.

KW - 18F-FDG PET/CT

KW - Extramedullary leukemia

KW - Gemtuzumab ozogamicin

UR - http://www.scopus.com/inward/record.url?scp=85063641625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063641625&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000001201

DO - 10.1097/MPH.0000000000001201

M3 - Article

C2 - 29734213

AN - SCOPUS:85063641625

SN - 1077-4114

VL - 41

SP - E174-E176

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 3

ER -

Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this